RESUMEN
Validation of the antimicrobial performance of contact-killing polymer surfaces through the experimental determination of bacterial adhesion or viability, is essential for their targeted development and application. However, there is not yet a consensus on the single most appropriate evaluation method or procedure. Combining and benchmarking previously reported assays could reduce the significant variation and misinterpretation of efficacy data obtained from different methods. In this work, we systematically investigated the response of bacterial cells to antiadhesive and antiseptic polymer coatings by combining (i) bulk solution-based, (ii) thin-film spacer-based, and (iii) direct-contact assays. In addition, we evaluated the studied assays using a five-point scoring framework that highlights key areas for improvement. Our data suggest that combined microscopy assays provide a more comprehensive representation of antimicrobial performance, thereby helping to identify effective types of antibacterial polymer coatings. IMPORTANCE We present and evaluate a combination of methods for validating the efficacy of antimicrobial surfaces. Antimicrobial surfaces/coatings based on contact-killing components can be instrumental to functionalize a wide range of products. However, there is not yet a consensus on the single, most appropriate method to evaluate their performance. By combining three microscopy methods, we were able to discern contact-killing effects at the single-cell level that were not detectable by conventional bulk microbiological analyses. The developed approach is considered advantageous for the future targeted development of robust and sustainable antimicrobial surfaces.
Asunto(s)
Antiinfecciosos , Polímeros , Antibacterianos/farmacología , Antiinfecciosos/farmacología , Bacterias , Microscopía , Polímeros/farmacología , Propiedades de SuperficieRESUMEN
OBJECTIVES: For stage IV pulmonary large cell neuroendocrine carcinoma (LCNEC), the only therapeutic option is palliative chemotherapy. DLL3 is a new therapeutic target, which seems to be often expressed in SCLC and LCNEC. It has recently been reported that DLL3 mRNA expression is particularly upregulated in the LCNEC subgroup with STK11/KEAP1 and TP53 co-mutations, in contrast to lower expression levels in RB1 and TP53 co-mutated LCNEC. Our aim was to investigate DLL3 protein expression in stage IV LCNEC and correlate data with mutational profiles (i.e.STK11/KEAP1/RB1), immunostaining results (pRb, NE markers) and clinical characteristics. MATERIALS AND METHODS: Immunohistochemical analysis for DLL3 (SC16.65) and ASCL1 (SC72.201) was performed on 94 and 51 FFPE tissue sections, respectively, of pathologically reviewed stage IV LCNEC. DLL3 and ASCL1 were scored positive if ≥1% of the tumor cells showed cytoplasmic/membranous or dotlike (DLL3) or nuclear (ASCL1) immunostaining. Data were correlated with available sequencing (TP53, RB1, STK11, KEAP1), immunostaining (pRb, NE markers) and clinical data. RESULTS: DLL3 was expressed in 70/94 (74%) LCNEC, 56 (80%) of which showed cytoplasmic/membranous staining. Median H-score was 55 (interquartile range 0-160). DLL3 staining was not different in pRb immunohistochemistry negative and positive patients (DLL3+ in 53/70 (76%) vs. 14/21 (67%), pâ¯=â¯0.409) or RB1 mutated and wildtype patients (DLL3+ in 27/34 (79%) vs. 23/33 (70%), pâ¯=â¯0.361). Nevertheless, 6/6 (100%) STK11 mutated, 10/11 (91%) KEAP1 mutated and 9/9 (100%) TP53 wildtype tumors were DLL3+â¯. Furthermore, DLL3 expression was associated with expression of ASCL1 and at least 2 out of 3 neuroendocrine markers. CONCLUSION: The high percentage (74%) of DLL3 expression in stage IV LCNEC denotes the potential of DLL3 targeted therapy in this patient group.
Asunto(s)
Carcinoma de Células Grandes/metabolismo , Carcinoma de Células Grandes/patología , Carcinoma Neuroendocrino/metabolismo , Carcinoma Neuroendocrino/patología , Péptidos y Proteínas de Señalización Intracelular/metabolismo , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/patología , Proteínas de la Membrana/metabolismo , Anciano , Biomarcadores de Tumor/genética , Biomarcadores de Tumor/metabolismo , Carcinoma de Células Grandes/genética , Carcinoma Neuroendocrino/genética , Femenino , Humanos , Inmunohistoquímica , Péptidos y Proteínas de Señalización Intracelular/biosíntesis , Péptidos y Proteínas de Señalización Intracelular/genética , Neoplasias Pulmonares/genética , Masculino , Proteínas de la Membrana/biosíntesis , Proteínas de la Membrana/genética , Persona de Mediana Edad , Mutación , Estadificación de Neoplasias , Pronóstico , Estudios RetrospectivosRESUMEN
The aim of quality management in medicine must be to increase the safety of treatment, to optimize the treatment results, but also to confirm economic justifiability. Participation in multiagency quality assurance measures should create the possibility to assess the quality of the services offered compared with other service providers and to recognize and correct corresponding deficits. Comparative examinations and assessments should serve to improve the quality of the results. The benefits of quality management as an important approach to promoting patient safety should be made known to all stakeholders. Patient-oriented process optimization and patient satisfaction are the focus. Furthermore, quality management should help increase the satisfaction of everyone involved in the process.
Asunto(s)
Atención a la Salud/normas , Legislación Médica , Médicos/normas , Garantía de la Calidad de Atención de Salud , Mejoramiento de la Calidad , Indicadores de Calidad de la Atención de Salud , Humanos , Responsabilidad LegalRESUMEN
We present a case of a male kidney transplant patient harbouring two kidney grafts of which one is functional. In the failed graft, he developed urothelial cell carcinoma with cells containing XX-chromosome, and female tumour cells were also found in the bladder. The patient underwent donor nephrectomy, was treated with epirubicin bladder instillations, and immunosuppression was tapered. Less than a year before re-transplantation a CT scan showed no abnormalities of the first graft. Transplantectomy before a second kidney transplantation is debated.
Asunto(s)
Carcinoma Papilar/etiología , Neoplasias Renales/etiología , Trasplante de Riñón/efectos adversos , Neoplasias de la Vejiga Urinaria/etiología , Carcinoma Papilar/genética , Carcinoma Papilar/patología , Femenino , Genotipo , Supervivencia de Injerto , Humanos , Hibridación Fluorescente in Situ , Fallo Renal Crónico/cirugía , Masculino , Persona de Mediana Edad , Neoplasias de la Vejiga Urinaria/genética , Neoplasias de la Vejiga Urinaria/patologíaRESUMEN
Purpose: The clinical use of detailed fetal neurosonography has increased over the past decade. This retrospective study explored the spectrum and frequency of different forms of corpus callosum anomalies (CCAs) in a level III center setting. Materials and Methods: Between 1999 and 2012, 48â907 detailed second and third trimester scans were performed. Among them, 140 (0.29â%) cases of CCA were diagnosed. We differentiated between complete and partial agenesis, hypoplastic corpus callosum (CC) and isolated and non-isolated forms. Results: The 140 cases with CCA included 107 with complete agenesis (76â%), 20 with partial agenesis (14â%) and 13 with a hypoplastic CC (9â%). Of them, 29â% (41/140) were isolated and 71â% (99/140) were non-isolated cases. Analysis of three time periods demonstrated an increase in the diagnosis of all types of CCA (1999â-â2004: nâ=â26; 2005â-â2008: nâ=â32; 2009â-â2012: nâ=â82), whereas the ratio between isolated and non-isolated types remained stable. The median gestational age at diagnosis was 25.0 weeks and did not change over the years. Non-isolated forms were associated with additional non-chromosomal cerebral anomalies in 22.2â% (22/99), extracerebral non-chromosomal malformations in 40.4â% (40/99), aneuploidies in 21.2â% (21/99), and syndromes in 16.2â% (16/99). All aneuploid fetuses except one showed cerebral or extracerebral malformations. Conclusion: The rise in prenatal diagnosis of CCA reflects the increased use of systematic fetal neurosonography over the years. Despite an overall increase in diagnosed cases, the relationship between isolated CCAs and complex forms remained stable. Since the percentage of coexisting anomalies is high, a detailed assessment by a specialist is recommended.
Asunto(s)
Agenesia del Cuerpo Calloso/diagnóstico por imagen , Ultrasonografía Doppler Transcraneal/métodos , Ultrasonografía Prenatal/métodos , Anomalías Múltiples/diagnóstico por imagen , Anomalías Múltiples/epidemiología , Agenesia del Cuerpo Calloso/epidemiología , Agenesia del Cuerpo Calloso/genética , Cuerpo Calloso/diagnóstico por imagen , Estudios Transversales , Femenino , Predisposición Genética a la Enfermedad/genética , Humanos , Interpretación de Imagen Asistida por Computador/métodos , Cariotipificación , Embarazo , Segundo Trimestre del Embarazo , Tercer Trimestre del Embarazo , Estudios Retrospectivos , SíndromeRESUMEN
PURPOSE: The introduction of non-invasive prenatal testing (NIPT) by isolation of cell-free fetal DNA from maternal blood is a new diagnostic option in prenatal care. The aim of the study was to investigate the algorithm of prenatal testing before and after the introduction of NIPT in a tertiary referral center and to investigate the influence of NIPT on the frequency of invasive procedures. METHODS: Retrospective data analysis was conducted of all singleton pregnancies that presented for first trimester screening 17 months before and after the introduction of NIPT (n = 2271). Women were categorized into three risk groups: low risk for trisomy 21 (<1:1000), intermediate risk (1:101-1:1000) and high risk (≥1:100). The choice of diagnostic testing after FTS was analyzed. RESULTS: 1093 (group 1) presented before and 1178 (group 2) after the introduction of NIPT. The rate of high-risk patients was equal in both groups (14.4 vs. 15.4 %). No differences were found with regard to invasive testing (11.6 vs. 11.3 %). NIPT was chosen by 3.7 % (44/1178) in group 2. Of those with NIPT, 72.7 % had a risk estimate of <1:100, but 90.9 % were ≥35 years old. The rate of NIPT among high-risk patients with a normal ultrasound examination was 25 %. CONCLUSION: At present, NIPT is chosen mainly for reassurance by patients not considered to be at high risk. In the high-risk group, NIPT can be offered if the ultrasound examination is normal and the risk is high due to maternal age or serum screening alone. The rate of invasive testing was not reduced in this selected population.